Note: PO = oral. a Conforms to dosing information listed in the manufacturer's labeling Volume 49, September 2014 13%, 15, 18 (grade 3 or 4) 1% 15 ; pyrexia 24%, 15 (grade 3 or 4) 2%. 15 
Dermatologic:
Bruising (grade 1 or 2) 18%, 18 contusion 11%, 15 maculopapular rash (grade 3 or 4) 10%. 17 
Gastrointestinal:
Constipation 15% 15 ; diarrhea 3% to 70%, 15, 17, 18 (grade 2 or higher) 2%, 16 (grade 3 or 4) 4% 15 ; mucositis (grade 3) 3% 18 ; nausea 26% to 67%, 15, 17 (grade 3 or 4) 2% 15 ; stomatitis 11%, 15 (grade 2 or higher) 2%, 16 15%, 21 (grade 2) 2% 21 ; fatigue 41%, 21 (grade 1) 20%, 21 (grade 2) 17%, 21 (grade 3) 5% 21 ; rash 15%, (grade 1) 10%, 21 (grade 2) 4%, 21 (grade 3) 2%. 21 
Anorexia 21%, (grade 1) 10%, 21 (grade 2) 9%, 21 (grade 3) 2% 21 ; constipation 25%, 21 (grade 1) 18%, 21 (grade 2) 7% 21 ; diarrhea 50%, 21 (grade 1) 32%, 21 (grade 2) 12%, 21 (grade 3) 6% 21 ; nausea 31%, 21 (grade 1) 23%, 21 (grade 2) 7% 21 ; vomiting (23%, (grade 1) 17%, 21 (grade 2) 5%. 21 5. Hematologic: Neutropenia 18%, 21 (grade 1) 1%, 21 (grade 2) 1%, 21 (grade 3) 6%, 21 (grade 4) 10% 21 ; thrombocytopenia 18%, 21 (grade 1) 4%, 21 (grade 2) 4%, 21 (grade 3) 7%, 21 (grade 4) 4%. 21 6. Infection: Upper respiratory tract 23%, (grade 1) 5%, 21 (grade 2) 18%. 21 7. Pulmonary: Cough 18%, 21 (grade 1) 12%, 21 (grade 2) 6% 21 ; dyspnea 27%, 21 10 1. Creatinine clearance (Cl cr ) greater than 25 mL/min, no adjustment required. 2. Cl cr less than 25 mL/min, no information available.
Name: Ramucirumab
Synonyms: Cyramza, IMC-1121B, LY3009806
MECHANISM OF ACTION
Ramucirumab is a monoclonal antibody that binds to the extracellular domain of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2). By binding to VEGFR-2, ramucirumab blocks VEGF signaling, resulting in inhibition of angiogenesis and cell metasteses. [26] [27] [28] [29] 
PHARMACOKINETICS
Following an 8 mg/kg infusion given weekly, ramucirumab has a peak concentration (C max ) of 325 mcg/mL following the initial infusion and 497 mcg/mL following multiple infusions. It has an AUC of 43,824 ng•h/mL and 132,789 ng•h/mL following the initial and multiple infusions, respectively, with a clearance of 0.190 mL/h/kg and 0.067 mL/h/kg following the initial and multiple infusions.
The elimination T½ is 123 hours and 318 hours following the initial and multiple infusions, respectively. 30 Following a 10 mg/kg infusion weekly, the peak concentration (C max ) is 406 mcg/mL following the initial infusion and 616 mcg/mL following multiple infusions. The AUC is 40,333 ng•h/mL and 156,840 ng•h/mL following the initial and multiple infusions, respectively, with a clearance of 0.264 mL/h/kg and 0.069 mL/h/kg following the initial and multiple infusions. The elimination T½ is 110 hours and 205 hours following the initial and multiple infusions, respectively. 30 Selected therapeutic regimens of ramucirumab appear in Table 2 .
PREPARATION
A. Use ramucirumab injection 10 mg/mL or 50 mg/mL. B. Dilute the solution in 250 mL 0.9% sodium chloride injection (NS). 35 ; hypertension 16% to 46%, 33, 34, 40 (grade 3) 12%, 34 (grade 3 or 4) 7% to 15%, 33, 40, 42, 43 (grade 4) 2% 34 ; venous thromboembolism 4%, 33 (grade 3 or 4) 1%. 33 2. Central nervous system: Headache 38%, 34 (grade 1 or 2) 23%, 35 (grade 3) 2% to 10%. 34,39 3. Constitutional: Fatigue 36% to 62%, 33, 34 (grade 1, 2 or 3) 18%, 35 (grade 3) 8% to 10%, 34, 39 (grade 3 or 4) 4% to 7% 33, 42, 43 ; pain 29%, 33 (grade 3 or 4) 5% to 6%. 33 33 (grade 3 or 4) 2%. 33 11. Renal: Proteinuria 3%, 33 (grade 2) 3%, 35 (grade 3) 33%, 41 (grade 3 or 4) <1%. 33 
STABILITY

